• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immuron Limited

    2/28/25 4:43:32 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMRN alert in real time by email
    6-K 1 ea0232560-6k_immuron.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of February 2025

     

    Commission File Number: 001-38104

     

    IMMURON LIMITED

    (Name of Registrant)

     

    Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

     

    Yes ☐       No ☒

     

    If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

     

     

     

     

     

     

    IMMURON LIMITED

     

    EXPLANATORY NOTE

     

    Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on February 28, 2025 titled:

     

    -“Appendix 4D and Half Year Report”

     

    A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

     

    This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

     

    1

     

     

    EXHIBITS

     

    Exhibit
    Number
      Description
    99.1  Appendix 4D and Half Year Report

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      IMMURON LIMITED
         
    Date: February 28, 2025 By: /s/ Phillip Hains
        Phillip Hains
        Company Secretary

     

    3

     

    Get the next $IMRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMRN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immuron Travelan® highest sales in history

      Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce contin

      4/10/25 6:00:00 PM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

      MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron's product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will

      3/5/25 6:00:00 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

      MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

      2/19/25 6:00:00 AM ET
      $AEMD
      $ASPI
      $BDRX
      $BENF
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials

    $IMRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Immuron Board Changes

      MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with significant positive change. We have accelerated our commercial activities through higher level of marketing, improved channel management and strategic intent. Our scientific endeavours are bearing results with strong clinical data supporting IMC's unique hyper-immune colos

      5/31/24 6:00:00 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer

      MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Steven Lydeamore as Chief Executive Officer (CEO) of the Company effective 27 June 2022. Mr. Lydeamore has 30 years international pharmaceutical experience, working in Australia, Canada and USA. Mr. Lydeamore brings valuable international experience having spent eleven years working at Canadian global pharmaceutical company Apotex Inc., and four years for Mayne Pharma (USA) Limited. This i

      5/5/22 8:22:54 PM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appointment of Paul Brennan as Non-Executive Director

      MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the appointment of Paul Brennan as an independent Non-Executive Director of the Company with effect from today. Mr Brennan has extensive experience in the health system through his clinical background and commercial exposure with various multinational companies. Mr Brennan was Chief Executive Officer (CEO) of PolyNovo Limited (ASX:PNV) for 7 years from 2015 to 2021 and took the company from $30M to a high

      3/16/22 9:30:00 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMRN
    SEC Filings

    See more
    • SEC Form 6-K filed by Immuron Limited

      6-K - Immuron Ltd (0001660046) (Filer)

      4/11/25 6:30:02 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Immuron Limited

      6-K - Immuron Ltd (0001660046) (Filer)

      4/10/25 8:00:04 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Immuron Limited

      6-K - Immuron Ltd (0001660046) (Filer)

      3/7/25 6:13:29 AM ET
      $IMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care